Literature DB >> 20098431

Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.

Stefan Stein1, Marion G Ott, Stephan Schultze-Strasser, Anna Jauch, Barbara Burwinkel, Andrea Kinner, Manfred Schmidt, Alwin Krämer, Joachim Schwäble, Hanno Glimm, Ulrike Koehl, Carolin Preiss, Claudia Ball, Hans Martin, Gudrun Göhring, Kerstin Schwarzwaelder, Wolf-Karsten Hofmann, Kadin Karakaya, Sandrine Tchatchou, Rongxi Yang, Petra Reinecke, Klaus Kühlcke, Brigitte Schlegelberger, Adrian J Thrasher, Dieter Hoelzer, Reinhard Seger, Christof von Kalle, Manuel Grez.   

Abstract

Gene-modified autologous hematopoietic stem cells (HSC) can provide ample clinical benefits to subjects suffering from X-linked chronic granulomatous disease (X-CGD), a rare inherited immunodeficiency characterized by recurrent, often life-threatening bacterial and fungal infections. Here we report on the molecular and cellular events observed in two young adults with X-CGD treated by gene therapy in 2004. After the initial resolution of bacterial and fungal infections, both subjects showed silencing of transgene expression due to methylation of the viral promoter, and myelodysplasia with monosomy 7 as a result of insertional activation of ecotropic viral integration site 1 (EVI1). One subject died from overwhelming sepsis 27 months after gene therapy, whereas a second subject underwent an allogeneic HSC transplantation. Our data show that forced overexpression of EVI1 in human cells disrupts normal centrosome duplication, linking EVI1 activation to the development of genomic instability, monosomy 7 and clonal progression toward myelodysplasia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20098431     DOI: 10.1038/nm.2088

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  59 in total

1.  Translocation t(2;3)(p15-23;q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features.

Authors:  M Stevens-Kroef; B Poppe; S van Zelderen-Bhola; E van den Berg; M van der Blij-Philipsen; A Geurts van Kessel; R Slater; G Hamers; L Michaux; F Speleman; A Hagemeijer
Journal:  Leukemia       Date:  2004-06       Impact factor: 11.528

2.  Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis.

Authors:  Yang Du; Sally E Spence; Nancy A Jenkins; Neal G Copeland
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

3.  Translocation (3;8)(q26;q24): a recurrent chromosomal abnormality in myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Pei Lin; L Jeffrey Medeiros; C Cameron Yin; Lynne V Abruzzo
Journal:  Cancer Genet Cytogenet       Date:  2006-04-01

4.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

5.  MLL5 contributes to hematopoietic stem cell fitness and homeostasis.

Authors:  Yan Zhang; Jasmine Wong; Mark Klinger; Mary T Tran; Kevin M Shannon; Nigel Killeen
Journal:  Blood       Date:  2008-09-25       Impact factor: 22.113

6.  High-resolution analysis of cytosine methylation in the 5ĺong terminal repeat of retroviral vectors.

Authors:  L Wang; P B Robbins; D A Carbonaro; D B Kohn
Journal:  Hum Gene Ther       Date:  1998-11-01       Impact factor: 5.695

7.  EVI1 induces myelodysplastic syndrome in mice.

Authors:  Silvia Buonamici; Donglan Li; Yiqing Chi; Rui Zhao; Xuerong Wang; Larry Brace; Hongyu Ni; Yogen Saunthararajah; Giuseppina Nucifora
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

8.  MLL5, a trithorax homolog, indirectly regulates H3K4 methylation, represses cyclin A2 expression, and promotes myogenic differentiation.

Authors:  Soji Sebastian; Prethish Sreenivas; Ramkumar Sambasivan; Sirisha Cheedipudi; Prashanth Kandalla; Grace K Pavlath; Jyotsna Dhawan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-05       Impact factor: 11.205

9.  Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1.

Authors:  Leopoldo Laricchia-Robbio; Giuseppina Nucifora
Journal:  Blood Cells Mol Dis       Date:  2007-10-29       Impact factor: 3.039

10.  Patterns of Evi-1 expression in embryonic and adult tissues suggest that Evi-1 plays an important regulatory role in mouse development.

Authors:  A S Perkins; J A Mercer; N A Jenkins; N G Copeland
Journal:  Development       Date:  1991-02       Impact factor: 6.868

View more
  331 in total

1.  Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.

Authors:  Xiyun Deng; Yanna Cao; Yan Liu; Fazhi Li; Kamalanathan Sambandam; Srinivasan Rajaraman; Archibald S Perkins; Alan P Fields; Mark R Hellmich; Courtney M Townsend; E Aubrey Thompson; Tien C Ko
Journal:  Mol Carcinog       Date:  2011-12-07       Impact factor: 4.784

2.  Gene therapy for SCID-X1: focus on clinical data.

Authors:  Christopher Baum
Journal:  Mol Ther       Date:  2011-12       Impact factor: 11.454

Review 3.  Safe harbours for the integration of new DNA in the human genome.

Authors:  Michel Sadelain; Eirini P Papapetrou; Frederic D Bushman
Journal:  Nat Rev Cancer       Date:  2011-12-01       Impact factor: 60.716

Review 4.  Hematopoietic stem cell engineering at a crossroads.

Authors:  Isabelle Rivière; Cynthia E Dunbar; Michel Sadelain
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

5.  Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts.

Authors:  Arianna Moiani; Ylenia Paleari; Daniela Sartori; Riccardo Mezzadra; Annarita Miccio; Claudia Cattoglio; Fabienne Cocchiarella; Maria Rosa Lidonnici; Giuliana Ferrari; Fulvio Mavilio
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

6.  Gene therapy: too much splice can spoil the dish.

Authors:  Didier Trono
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

7.  High-throughput, sensitive quantification of repopulating hematopoietic stem cell clones.

Authors:  Sanggu Kim; Namshin Kim; Angela P Presson; Dong Sung An; Si Hua Mao; Aylin C Bonifacino; Robert E Donahue; Samson A Chow; Irvin S Y Chen
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

8.  Lentiviral vector gene therapy: effective and safe?

Authors:  Derek A Persons
Journal:  Mol Ther       Date:  2010-05       Impact factor: 11.454

Review 9.  Gene therapy for hemoglobinopathies: the state of the field and the future.

Authors:  Shanmuganathan Chandrakasan; Punam Malik
Journal:  Hematol Oncol Clin North Am       Date:  2014-04       Impact factor: 3.722

10.  Efficiency and safety of O⁶-methylguanine DNA methyltransferase (MGMT(P140K))-mediated in vivo selection in a humanized mouse model.

Authors:  Ruhi Phaltane; Reinhard Haemmerle; Michael Rothe; Ute Modlich; Thomas Moritz
Journal:  Hum Gene Ther       Date:  2014-01-07       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.